Qianhui Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Qianhui Hong has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Fanhua Kang
Department of Pathology, Xiangya Changde Hospital, Changde 415000, Hunan, China
1 shared publication- Jianbo Li
Department of Pathology, Xiangya Changde Hospital, Changde 415000, Hunan, China
1 shared publication - Jinwu Peng
Department of Pathology Xiangya Hospital Central South University Changsha China
1 shared publication - Qingchun He
Department of Emergency, Xiangya Hospital, Central South University, Changsha, China
1 shared publication - Wei Liu
State Key Laboratory of Food Science and Resources Nanchang University Nanchang China
1 shared publication - Wenqin Zhang
Department of Pathology, The Fourth Hospital of Changsha (Integrated Traditional Chinese and Western Medicine Hospital of Changsha, Changsha Hospital of Hunan Normal University), Changsha, China
1 shared publication
Latest Publications
- Open Access
- 21 February 2022
- Published by Impact Journals, LLC in Aging
- Vol. 14 (4) , 1822-1835
Downregulated exosome-associated gene FGF9 as a novel diagnostic and prognostic target for ovarian cancer and its underlying roles in immune regulation
Exosome has been demonstrated to be secreted from cells and seized by targeted cells. Exosome could transmit signals and exert biological functions in cancer progression. Nevertheless, the underlying mechanisms of exosome in ovarian cancer (OC) have not been fully explored. In this study, we wanted to explore whether Fibroblast growth factor 9 (FGF9), as an exosome-associated gene, was importantly essential in OC progression and prognosis. Firstly, comprehensive bioinformatics platforms were applied to find that FGF9 expression was lower in OC tissues compared to normal ovarian tissues. Meanwhile, downregulated FGF9 displayed favorable prognostic values in OC patients. The gene enrichment of biological functions indicated that abnormally expressed FGF9 could be involved in the OC-related immune signatures, such as immunoinhibitors and chemokine receptors. Taken together, these findings could provide a novel insight into the significance of FGF9 in OC progress and supply a new destination of FGF9-related immunotherapy in clinical treatment.
- 21 February 2022
- Published by Impact Journals, LLC in Aging
- Vol. 14 (4) , 1822-1835
Open AccessDownregulated exosome-associated gene FGF9 as a novel diagnostic and prognostic target for ovarian cancer and its underlying roles in immune regulation
Exosome has been demonstrated to be secreted from cells and seized by targeted cells. Exosome could transmit signals and exert biological functions in cancer progression. Nevertheless, the underlying mechanisms of exosome in ovarian cancer (OC) have not been fully explored. In this study, we wanted to explore whether Fibroblast growth factor 9 (FGF9), as an exosome-associated gene, was importantly essential in OC progression and prognosis. Firstly, comprehensive bioinformatics platforms were applied to find that FGF9 expression was lower in OC tissues compared to normal ovarian tissues. Meanwhile, downregulated FGF9 displayed favorable prognostic values in OC patients. The gene enrichment of biological functions indicated that abnormally expressed FGF9 could be involved in the OC-related immune signatures, such as immunoinhibitors and chemokine receptors. Taken together, these findings could provide a novel insight into the significance of FGF9 in OC progress and supply a new destination of FGF9-related immunotherapy in clinical treatment.